Results of New Study on the Economic Burden of Parkinson’s Disease Finds That the Total Yearly Cost is $52 Billion, Doubling Previous Estimates
KINGSTON, N.J. (June 25, 2019) Recently on June 13, 2019, the Michael J. Fox Foundation for Parkinson’s Research announced critical findings of the annual economic burden of Parkinson’s disease on patients, their families, and the United States government. The study, entitled The Economic Burden of Parkinson’s Disease, found that the annual Parkinson’s disease economic toll is $51.9 billion every year, doubling previous estimates.
Within the total yearly cost, $25.4 billion is associated with direct medical costs (such as hospitalizations and medication), while $26.5 billion is for non-medical costs (such as missed work, lost wages, early forced retirement, and family caregiver time). As stated on MJFF’s press release, “This new study provides the most comprehensive assessment of the total economic burden on patients, care partners, payers, employers, healthcare systems and government programs. For many years, the financial impact of the disease has been vastly underestimated.”
The Michael J. Fox Foundation conducted and published the study, with support from national organizations like us, and industry partners. “I am pleased to share with you that The Parkinson Alliance helped support this important new study,” said Carol J. Walton, President & CEO of The Parkinson Alliance. “The findings of the study give us knowledge of how patients, their families, and the government are impacted by the cost of Parkinson’s disease. The data is a critical indicator for the need to keep taking action to help decrease the economic burden by funding important research,” added Walton.
For more information on the results of this research, The Parkinson Alliance urges you to read the press release issued by the Michael J. Fox Foundation. We also encourage you to share this information with Congress today; please visit MJFF’s website and send an email to your senators and representatives to let them know about this new study and why Parkinson’s research matters to people with Parkinson’s disease.